Abstract
Pigment epithelium-derived factor (PEDF) is a potent inhibitor of angiogenesis, suggesting that loss of this factor may be involved in angiogenic eye disease. Here, we show that PEDF inhibits angiotensin II-induced smooth muscle cell proliferation through its anti-oxidative properties. Our present study suggests that PEDF may play a protective role against atherosclerosis.
Keywords: Angiotensin II, atherosclerosis, oxidative stress, PEDF
Protein & Peptide Letters
Title: Pigment Epithelium-Derived Factor (PEDF) Inhibits Angiotensin IIInduced Smooth Muscle Cell Proliferation Through Its Anti-Oxidative Properties
Volume: 14 Issue: 6
Author(s): Sho-ichi Yamagishi, Takanori Matsui, Kazuo Nakamura and Tsutomu Imaizumi
Affiliation:
Keywords: Angiotensin II, atherosclerosis, oxidative stress, PEDF
Abstract: Pigment epithelium-derived factor (PEDF) is a potent inhibitor of angiogenesis, suggesting that loss of this factor may be involved in angiogenic eye disease. Here, we show that PEDF inhibits angiotensin II-induced smooth muscle cell proliferation through its anti-oxidative properties. Our present study suggests that PEDF may play a protective role against atherosclerosis.
Export Options
About this article
Cite this article as:
Sho-ichi Yamagishi , Takanori Matsui , Kazuo Nakamura and Tsutomu Imaizumi , Pigment Epithelium-Derived Factor (PEDF) Inhibits Angiotensin IIInduced Smooth Muscle Cell Proliferation Through Its Anti-Oxidative Properties, Protein & Peptide Letters 2007; 14 (6) . https://dx.doi.org/10.2174/092986607780989976
DOI https://dx.doi.org/10.2174/092986607780989976 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Lipid-Lowering Therapies for Atherosclerosis: Statins, Fibrates, Ezetimibe and PCSK9 Monoclonal Antibodies
Current Medicinal Chemistry Phytochemical-Mediated Glioma Targeted Treatment: Drug Resistance and Novel Delivery Systems
Current Medicinal Chemistry Vildagliptin Restores Renal Myogenic Function and Attenuates Renal Sclerosis Independently of Effects on Blood Glucose or Proteinuria in Zucker Diabetic Fatty Rat
Current Vascular Pharmacology Elevated Serum Human Cytomegalovirus IgM Levels in the Acute Phase of Ischemic Stroke are Associated with Increased Risk of Death and Major Disability
Current Neurovascular Research Point of Care Cardiac Ultrasound Applications in the Emergency Department and Intensive Care Unit - A Review
Current Cardiology Reviews Caspases as Drug Targets in Ischemic Organ Injury
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Editorial (Thematic Issue: Modifying Cardiovascular Risk Factors: Current Opinion and Future Trends)
Current Pharmaceutical Design Neurotoxicity by Synthetic Androgen Steroids: Oxidative Stress, Apoptosis, and Neuropathology: A Review
Current Neuropharmacology Strategies to Avoid TAVI-related Acute Kidney Injury
Current Pharmaceutical Design Disturbed Homeostasis in Patients with Acute Psychosis
Current Psychiatry Reviews The Influence of a Half-Marathon Race Upon Cardiac Troponin T Release in Adolescent Runners
Current Medicinal Chemistry Implications of Fibroblast Growth Factors (FGFs) in Cancer: From Prognostic to Therapeutic Applications
Current Drug Targets Oxidative Stress in the ICU
Current Nutrition & Food Science Coronary Artery Bypass Graft in HIV-Infected Patients: A Multicenter Case Control Study
Current HIV Research A PHACES Syndrome Unmasked by Propranolol Interruption in a Tetralogy of Fallot Patient: Case Report and Extensive Review on New Indications of Beta Blockers
Current Medicinal Chemistry In the Search of the Vulnerable Plaque: Current Diagnostic Techniques and Future Directions
Vascular Disease Prevention (Discontinued) Coronary Microcirculation in Heart Failure with Preserved Systolic Function
Current Pharmaceutical Design Maintaining Plasma Fibrinogen Levels and Fibrinogen Replacement Therapies for Treatment of Intracranial Hemorrhage
Current Drug Targets Cytokines and Chemokines as Regulators of Angiogenesis in Health and Disease
Current Pharmaceutical Design Phytochemical Genistein in the Regulation of Vascular Function: New Insights
Current Medicinal Chemistry